Patent
Use of adenosine derivatives as anti-allergic compounds and pharmaceutical compositions containing them
Wolfgang Prof Dr Med Schaumann,Otto-Henning Wilhelms,Andronika Dr. Med. Roesch,Wolfgang Dr Rer Nat Kampe +3 more
Reads0
Chats0
TLDR
In this article, the use of adenosine derivatives for the treatment of allergic diseases, as well as for bronchosphatic and broncho-constrictive reactions brought about by inflammation, is discussed.Abstract:
The present invention is concerned with the use of adenosine derivatives for the treatment of allergic diseases, as well as for bronchosphatic and broncho-constrictive reactions brought about by inflammation. The above adenosine derivatives can be used alone or together with xanthine derivatives. The invention is further concerned with compositions containing compounds of adenosine derivatives and optionally compounds of xanthine derivatives together with appropriate pharmaceutical carriers.read more
Citations
More filters
Patent
Heterocyclic compounds and uses thereof
Alfredo C. Castro,Catherine A. Evans,Somarajannair Janardanannair,Andre Lescarbeau,Tao Liu,Daniel A. Snyder,Martin R. Tremblay,Pingda Ren,Yi Liu,Liansheng Li,Katrina Chan +10 more
TL;DR: In this article, compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activation, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activations are described.
Patent
Certain chemical entities, compositions and methods
TL;DR: In this paper, chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 Kinase activity are described.
Journal ArticleDOI
Adenosine: The prototypic neuromodulator.
TL;DR: Data indicate that adenosine, like the many peptides currently being studied, is a homeostatic neuromodulator and as such may represent the prototypic agent of this type.
Patent
Heterocyclic kinase inhibitors
TL;DR: In this paper, the authors provide heterocyclic compounds for use as P13 kinase inhibitors and in other applications, as well as pharmaceutical compositions and methods of treatments of diseases and conditions associated with P 13 kinase activity.
Patent
Kinase inhibitors and methods of use
TL;DR: In this article, chemical entities or compounds and pharmaceutical compositions thereof are provided that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases.
References
More filters
Patent
N(6)-subst adenosine derivs - with coronary circulatory etc activity
Rolf Dr Pohlke,Werner Dr Mehrhof,Herbert Dr Nowak,Zdenek Dr Simane,Karl Heinz Dr Becker,Hans-Jochen Dr Schliep +5 more
TL;DR: In this paper, the authors defined the therapeutically acceptable contiguity of 6-membered rings and their properties, including the ability to increase coronary flow and/or increase the oxygen partial pressure in coronary venous blood.
Patent
2-amino-adenosine derivatives
TL;DR: NOVEL 2-AMINO-ADENOSINE DRIVATIVES CHARACTERIZED by CARDIAC and CIRCULATORY ACTIVITY and by their high Coronary SPECIFICITY HAVING the FOLLOWING STRUCTURAL FORMULA: 2-NH2,6-(R1-N(-R2)-),9-(3,4,5-TRI(HO-)-2-TTERAHYDRO- PYRanyL)-9H-PURINE whereIN R1 is HYDR
Patent
Method of depressing fatty acids and triglycerides
TL;DR: The GENERA FORMULA 2-R1,6-(B-X-A-N(-R2)-),9-(3,4-DI(HO-),5-(HO-CH2-)- TETRAHYDROFUR-2-YL-)-9H-PURINE as mentioned in this paper.
Patent
N6-(1- and 2-benzocycloalkyl) adenosines
TL;DR: N 6 -(1 and 2-Benzocycloalkyl)adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, process for their manufacture, pharmaceutical compositions and methods for using said compounds and compositions are described as mentioned in this paper.
Patent
Antiallergic agent comprising derivatives of adenosine
TL;DR: In this paper, an antiallergic effect is exhibited by an N 6 -ω-aminoalkyl adenosine compound of the formula: where n is an integer of 1 to 20, and R is a β-D-ribofuranosyl group represented by the formula.